Pathophysiology of transcranial sonography signal changes in the human substantia Nigra

International Review of Neurobiology

Volumn 90, Issue C, 2010, Pages 107-120

  Double, Kay L ^a   Todd, Gabrielle ^b   Duma, Stephen R ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Hyperechogenicity; Iron; Magnetic resonance imaging; Neuromelanin; Parkinson's disease; Substantia nigra; Transcranial sonography

Indexed keywords

6 FLUORODOPA F 18; IRON;

ARTICLE; AUTOPSY; CELL COUNT; DIAGNOSTIC VALUE; DISEASE MODEL; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; ECHOGRAPHY; HUMAN; NERVE CELL NECROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; TRANSCRANIAL SONOGRAPHY;

EID: 77955374764     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(10)90008-1     Document Type: Chapter

References (59)

1. Antonini A., Leenders K.L., Meier D., Oertel W.H., Boesiger P., Anliker M. T2 relaxation time in patients with Parkinson's disease. Neurology 1993, 43:697-700.
2. Atasoy H.T., Nuyan O., Tunc T., Yorubulut M., Unal A., Inan L. T2-weighted MRI in Parkinson's disease; Substantia nigra pars compacta hypointensity correlates with the clinical scores. Neurol. India 2004, 52:332-337.
3. Bartzokis G., Cummings J.L., Markham C.H., Marmarelis P.Z., Treciokas L.J., Tishler T.A., Marder S.R., Mintz J. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn. Reson. Imaging 1999, 17:213-222.
4. Behnke S., Double K.L., Duma S., Broe G.A., Guenther V., Becker G., Halliday G.M. Substantia nigra echomorphology in the healthy very old: Correlation with motor slowing. NeuroImage 2007, 34:1054-1059.
5. Behnke S., Schroeder U., Dillmann U., Buchholz H.G., Schreckenberger M., Fuss G., Reith W., Berg D., Krick C.M. Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. NeuroImage 2009, 47:1237-1243.
6. Berg D. Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: Implications for idiopathic and monogenetic forms. Neurochem. Res. 2007, 32:1646-1654.
7. Berg D. Ultrasound in the (premotor) diagnosis of Parkinson's disease. Parkinsonism Rel. Disord. 2007, 13:S429-S433.
8. Berg D., Becker G., Zeiler B., Tucha O., Hofmann E., Preier M., Benz P., Jost W., Reiners K., Lange K.W. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999, 53:1026-1031.
9. Berg D., Grote C., Rausch W.D., Mäurer M., Wesemann W., Riederer P., Becker G. Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med. Biol. 1999, 25:901-904.
10. Berg D., Merz B., Reiners K., Naumann M., Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov. Disord. 2005, 20:383-385.
11. Berg D., Roggendorf W., Schroder U., Klein R., Tatschner T., Benz P., Tucha O., Preier M., Lange K.W., Reiners K., Gerlach M., Becker G. Echogenicity of the substantia nigra: Association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch. Neurol. 2002, 59:999-1005.
12. Berg D., Siefker C., Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J. Neurol. 2001, 248:684-689.
13. Berg D., Siefker C., Ruprecht-Dorfler P., Becker G. Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 2001, 56:13-17.
14. Collier T.J., Lipton J., Daley B.F., Palfi S., Chu Y., Sortwell C., Bakay R.A., Sladek J.R.J., Kordower J.H. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: Diminished compensatory mechanisms as a prelude to Parkinsonism. Neurobiol Dis. 2007, 26:56-65.
15. Dexter D.T., Wells F.R., Agid F., Agid Y., Lees A.J., Jenner P., Marsden C.D. Increased nigral iron content in postmortem Parkinsonian brain. Lancet. 1987, 2(8569):1219-1220.
16. 123 I-FP-CIT SPECT in Parkinson's disease and essential tremor. Mov. Disord. 2008, 23:405-410.
17. Double K.L., Gerlach M., Schünemann V., Trautwein A.X., Zecca L., Gallorini M., Youdim M.B., Riederer P., Ben-Shachar D. Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem. Pharmacol. 2003, 66:489-494.
18. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 1991, 114:2283-2301.
19. Fedorow H., Tribl F., Halliday G., Gerlach M., Riederer P., Double K.L. Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson's disease. Prog. Neurobiol. 2005, 75:109-124.
20. Godau J., Schweitzer K.J., Liepelt I., Gerloff C., Berg D. Substantia nigra hypoechogenicity: Definition and findings in restless legs syndrome. Mov. Disord. 2007, 22:187-192.
21. Gorell J.M., Ordidge R.J., Brown G.G., Deniau J.C., Buderer N.M., Helpern J.A. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995, 45:1138-1143.
22. Graham J.M., Paley M.N.J., Grunewald R.A., Hoggard N., Griffiths P.D. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 2000, 123:2423-2431.
23. Hagenah J.M., Becker B., Brüggemann N., Djarmati A., Lohmann K., Sprenger A., Klein C., Seidel G. Transcranial sonography findings in a large family with homozygous and heterozygous PINK1 mutations. J Neurol. Neurosurg. Psychiatry. 2008, 79:1071-1074.
24. Hardman C.D., McRitchie D.A., Halliday G.M., Cartwright H.R., Morris J.G. Substantia nigra pars reticulata neurons in Parkinson's disease. Neurodegeneration 1996, 5:49-55.
25. Hochstrasser H., Bauer P., Walter U., Behnke S., Spiegel J., Csoti I., Zeiler B., Bornemann A., Pahnke J., Becker G., Riess O., Berg D. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 2004, 63:1912-1917.
26. Hutchinson M., Raff U. Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. Am. J. Neuroradiol. 2000, 21:697-701.
27. Hutchinson M., Raff U. Detection of Parkinson's disease by MRI: Spin-lattice distribution imaging. Mov. Disord. 2008, 23:1991-1997.
28. Hutchinson M., Raff U., Lebedev S. MRI correlates of pathology in Parkinsonism: Segmented inversion recovery ratio imaging (SIRRIM). NeuroImage 2003, 20:1899-1902.
29. Iova A., Garmashov A., Androuchtchenko N., Kehrer M., Berg D., Becker G., Garmashov Y. Postnatal decrease in substantia nigra echogenicity. J. Neurol. 2004, 251:1451-1454.
30. Kosta P., Argyropoulou M., Markoula S., Konitsiotis S. MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease. J. Neurol. 2006, 253:26-32.
31. Lee C.S., Samii A., Sossi V., Ruth T.J., Schulzer M., Holden J.E., Wudel J., Pal P.K., de la Fuente-Fernandez R., Calne D.B., Stoessl A.J. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 2000, 47:493-503.
32. Martin W.R.W., Wieler M., Gee M. Midbrain iron content in early Parkinson disease: A potential biomarker of disease status. Neurology 2008, 70:1411-1417.
33. McRitchie D.A., Halliday G.M., Cartwright H. Quantitative analysis of the variability of substantia nigra pigmented cell clusters in the human. Neuroscience 1995, 68:539-551.
34. McRitchie D.A., Hardman C.D., Halliday G.M. Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. J. Comp. Neurol. 1996, 364:121-150.
35. Menke R.A., Scholz J., Miller K.L., Deoni S., Jbabdi S., Matthews P.M., Zarei M. MRI characteristics of the substantia nigra in Parkinson's disease: A combined quantitative T1 and DTI study. NeuroImage 2009, 47:435-441.
36. Michaeli S., Oz G., Sorce D.J., Garwood M., Ugurbil K., Majestic S., Tuite P. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov. Disord. 2007, 22:334-340.
37. Minati L., Grisoli M., Carella F., De Simone T., Bruzzone M.G., Savoiardo M. Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging. Am. J. Neuroradiol. 2007, 28:309-313.
38. Mondino F., Filippi P., Magliola U., Duca S. Magnetic resonance relaxometry in Parkinson's disease. Neurol. Sci. 2002, 23:s87-s88.
39. 18 F]dopa PET. J. Neurol. Neurosurg. Psychiatry 1998, 64:314-319.
40. Olanow C.W., Stern M.B., Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009, 72:S1-S136.
41. * -weighted MRI at 3 Tesla. Magn. Reson. Med. 1994, 32:335-341.
42. Raff U., Hutchinson M., Rojas G.M., Huete I. Inversion recovery MRI in idiopathic Parkinson disease is a very sensitive tool to assess neurodegeneration in the substantia nigra: Preliminary investigation. Acad. Radiol. 2006, 13:721-727.
43. Ruprecht-Dörfler P., Berg D., Tucha O., Benz P., Meier-Meitinger M., Alders G.L., Lange K.W., Becker G. Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's disease. NeuroImage 2003, 18:416-422.
44. Ruprecht-Dörfler P., Klotz P., Becker G., Berg D. Substantia nigra hyperechogenicity correlates with subtle motor dysfunction in tap dancers. Parkinsonism Relat. Disord. 2007, 13:362-364.
45. Sasaki M., Shibata E., Tohyama K., Takahashi J., Otsuka K., Tsuchiya K., Takahashi S., Ehara S., Terayama Y., Sakai A. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport 2006, 17:1215-1218.
46. Snyder A.M., Connor J.R. Iron, the substantia nigra and related neurological disorders. Biochim. Biophys. Acta 2009, 1790:606-614.
47. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., Youdim M.B. Increased iron (III) and total iron content in post mortem substantia nigra of Parkinsonian brain. J. Neural Transm 1988, 74:199-205.
48. 123 I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. Brain 2006, 129:1188-1193.
49. Stark A.K., Pakkenberg B. Histological changes of the dopaminergic nigrostriatal system in aging. Cell Tissue Res. 2004, 318:81-92.
50. Todd G., Taylor J.L., Baumann D., Butler J.E., Duma S.R., Hayes M., Carew-Jones F., Piguet O., Behnke S., Ridding M.C., Berg D., Double K.L. Substantia nigra echomorphology and motor cortex excitability. NeuroImage 2010, 50:1351-1356.
51. Tsai C.-F., Wu R.-M., Huang Y.-W., Chen L.-L., Yip P.-K., Jeng J.-S. Transcranial color-coded sonography helps differentiation between idiopathic Parkinson's disease and vascular Parkinsonism. J. Neurol. 2007, 254:501-507.
52. Vlaar A.M., Bouwmans A., Mess W.H., Tromp S.C., Weber W.E. Transcranial duplex in the differential diagnosis of Parkinsonian syndromes: A systematic review. J. Neurol. 2009, 256:530-538.
53. Vymazal J., Righini A., Brooks R.A., Canesi M., Mariani C., Leonardi M., Pezzoli G. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: Relation to iron content. Radiology 1999, 211:489-495.
54. Wallis L.I., Paley M.N.J., Graham J.M., Grünewald R.A., Wignall E.L., Joy H.M., Griffiths P.D. MRI assessment of basal ganglia iron deposition in Parkinson's disease. J. Magn. Reson. Imaging 2008, 28:1061-1067.
55. Walter U. Transcranial brain sonography findings in Parkinson's disease: Implications for pathogenesis, early diagnosis and therapy. Expert Rev. Neurother. 2009, 9:835-846.
56. Walter U., Dressler D., Wolters A., Wittstock M., Greim B., Benecke R. Sonographic discrimination of dementia with Lewy bodies and Parkinson's disease with dementia. J. Neurol. 2006, 253:448-454.
57. Walter U., Klein C., Hilker R., Benecke R., Pramstaller P.P., Dressler D. Brain parenchyma sonography detects preclinical Parkinsonism. Mov. Disord. 2004, 19:1445-1449.
58. Weise D., Lorenz R., Schliesser M., Schirbel A., Reiners K., Classen J. Substantia nigra echogenicity: A structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease. Mov. Disord. 2009, 24:1669-1675.
59. Zecca L., Berg D., Arzberger T., Ruprecht P., Rausch W.D., Musicco M., Tampellini D., Riederer P., Gerlach M., Becker G. In vivo detection of iron and neuromelanin by transcranial sonography: A new approach for early detection of substantia nigra damage. Mov. Disord. 2005, 20:1278-1285.